Trial reportNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2014
Topiramate for smoking cessation: a randomized, placebo-controlled pilot study.
Trial report in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00755716 (Topiramate Alone and in Combination With the Nicotine Patch for Smoking Cessation), which is not on this map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Topiramate Alone and in Combination With the Nicotine Patch for Smoking Cessation: A Pilot Study
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Interventions for preventing weight gain after smoking cessation.The Cochrane database of systematic reviews · 2021Pooled it
- Cessation classification likelihood increases with higher expired-air carbon monoxide cutoffs: a meta-analysis.Drug and alcohol dependence · 2021Pooled it
- Pooled it
- High- and low-dose topiramate for the treatment of persons with alcohol use disorder who smoke cigarettes: A randomized control trial.Alcohol, clinical & experimental research · 2025Trial
- Topiramate decreases the salience of motivationally relevant visual cues among smokers with alcohol use disorder.Alcoholism, clinical and experimental research · 2022Trial
- Behavioral economic analysis of topiramate pharmacotherapy for alcohol: a placebo-controlled investigation of effects on alcohol reinforcing value and delayed reward discounting.Psychopharmacology · 2022Trial
- Combined pharmacotherapy and evidence-based psychosocial Cannabis treatment for youth and selection of cannabis-using friends.Drug and alcohol dependence · 2021Trial
- Trial
- Predictors of Topiramate Tolerability in Heavy Cannabis-Using Adolescents and Young Adults: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial.Journal of clinical psychopharmacology · 2018Trial
- Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo-controlled pilot study.Addiction biology · 2017Trial
- Type A/Type B Alcoholism Predicts Differential Response to Topiramate in a Smoking Cessation Trial in Dually Diagnosed Men.Journal of studies on alcohol and drugs · 2017Trial
- A Randomized Trial Evaluating Whether Topiramate Aids Smoking Cessation and Prevents Alcohol Relapse in Recovering Alcohol-Dependent Men.Alcoholism, clinical and experimental research · 2017Trial
- Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-Induced Smoking Cessation.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2016Trial
- Balancing risk and benefit in heavy drinkers treated with topiramate: implications for personalized care.The Journal of clinical psychiatry · 2016Trial
- Dynamic associations between cannabis use and sleep in adolescents and young adults during a cannabis intervention trial.Journal of research on adolescence : the official journal of the Society for Research on Adolescence · 2025Article
- Treatment of Adolescent Cannabis Use Disorders.The Psychiatric clinics of North America · 2023Review
- Treatment of Adolescent Cannabis Use Disorders.Child and adolescent psychiatric clinics of North America · 2023Review
- Study title: A systematic review of RCTs to examine the risk of adverse cardiovascular events with nicotine use.Frontiers in cardiovascular medicine · 2023Review
- Consideration of sex and gender differences in addiction medication response.Biology of sex differences · 2022Review
- Topiramate for smoking cessation: Systematic review and meta-analysis.Tobacco prevention & cessation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
introductionTopiramate (TOP) blocks glutamate receptors and facilitates GABA (γ-aminobutyric acid) neurotransmission, effects that may facilitate smoking cessation. We compared the effects of behavioral counseling combined with (a) TOP, (b) TOP/nicotine patch (TOP/NIC), or (c) placebo (PLC) for smoking cessation.
methodsWe conducted a 10-week randomized trial in which subjects and research personnel were blinded to TOP versus PLC but not to the TOP/NIC patch condition. In groups receiving TOP, the medication dosage was titrated gradually up to 200 mg/day. The smoking quit date (QD) was scheduled after 2 weeks of medication treatment. NIC (21 mg) was started on the QD in subjects randomized to the TOP/NIC condition. The main outcome measure was the end-of-treatment, 4-week continuous abstinence rate (CAR; biochemically confirmed).
resultsFifty-seven subjects were randomized to treatment. The 4-week CAR was 1 of 19 (5%) in the PLC group, 5 of 19 (26%) in the TOP group, and 7 of 19 (37%) in the TOP/NIC group (p = .056). Pairwise comparisons showed a difference between TOP/NIC and PLC (p = .042) and a nonsignificant difference between TOP and PLC (p = .18). The PLC group gained 0.37 lb/week, the TOP group lost 0.41 lb/week, and the TOP/NIC group lost 0.07 lb/week (p = .004). Pairwise comparisons showed a difference between TOP and PLC (p < .001) and between TOP/NIC and PLC groups (p = .035). Paresthesia was more frequent in subjects on TOP than PLC (p = .011).
conclusionsTOP, alone or in combination with the NIC, resulted in a numerically higher quit rate than PLC and decreased weight. A larger, PLC-controlled trial is needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.